Evobrutinib-M2951-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEEvobrutinibCat. No.: HY-101215CAS No.: 1415823-73-2Synonyms: M2951; MSC2364447C分式: CHNO分量: 429.51作靶點: Btk作通路: Protein Tyrosine Kinase/RTK儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 6.4

2、mg/mL (14.90 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.3282 mL 11.6412 mL 23.2823 mL5 mM 0.4656 mL 2.3282 mL 4.6565 mL10 mM 0.2328 mL 1.1641 mL 2.3282 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Evobrutinib (M2951)服有效的、度選擇性的、BTK 的不可逆共價抑制劑，其IC50

3、 值為8.9 nM。Evobrutinib (M2951) 有治療免疫性疾病的潛能。體內(nèi)研究Evobrutinib (0.3, 1, 3, 10, or 30 mg/kg, oral gavage, once daily) demonstrates efficacy in a rat model ofrheumatoid arthritis 1.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEAnimal Model: Female Lewis rats with semi-established type II collagen arthri

4、tis 1.Dosage: 0.3, 1, 3, 10, or 30 mg/kg.Administration: Oral gavage once daily for 11 days (days 6-16).Result: Reduced ankle histopathology scores in a dose-dependent manner, compared to vehicle.戶使本產(chǎn)品發(fā)表的科研獻 Thromb Haemost. 2019 Mar;119(3):397-406. Drug Test Anal. 2019 Jan;11(1):129-139. Biomed Chro

5、matogr. 2019 May;33(5):e4507.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Caldwell R, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Brutons Tyrosine Kinase (BTK) Inhibitor forthe Treatment of Immunological Diseases. J Med Chem. 2019 Aug 1.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021